In recent years, the regulatory environment for life science companies has become less predictable, increasing the risks associated with innovation and investment. Industry veterans note that while the U.S. Food and Drug Administration (FDA) has always maintained rigorous standards, the current climate is marked by leadership changes, shifting policies, and evolving approval criteria.
A notable change is the FDA’s move toward approving drugs based on a single pivotal Phase 3 trial instead of the traditional two. This approach aims to reduce development time and costs, allowing products to reach the market faster. "According to FDA Commissioner Marty Makary, the agency plans to move toward requiring a single pivotal clinical study, rather than the traditional two, for many medical products. The stated goal is to accelerate approvals by reducing time and cost, based on the premise that a well-designed trial, supported by robust confirmatory evidence, can provide sufficient statistical confidence."
Industry leaders have responded with cautious optimism but also express concerns about potential drawbacks. Executives at major industry conferences have highlighted that relying on one trial could limit the breadth of clinical evidence and potentially weaken product labels. This could influence how physicians prescribe new therapies and affect market access.
To assess these concerns, consulting firm Litmys partnered with Doximity and physician Nicole Chase to survey 100 primary care and family practice doctors. The findings indicated that most physicians are indifferent to whether a drug is approved after one or two trials as long as it is adequately studied. Their main priorities are safety profile and duration of patient exposure.
Recent regulatory actions have added to industry anxiety. Several companies—including Corcept Therapeutics, Sanofi, Atara Biotherapeutics, Pierre Fabre, Replimmune, Capricor, Biohaven, and Moderna—have received unexpected complete response letters (CRLs) or outright refusals from the FDA despite meeting their primary clinical endpoints. In some cases, such as Moderna’s mRNA-based flu vaccine application in February 2026 (source), applications were not even reviewed despite prior agreement on trial design.
These developments reflect what some experts describe as more conservative interpretations of benefit-risk assessments by regulators (source). Sponsors who meet predefined objectives may still face rejections due to evolving standards rather than new negative data.
The FDA’s updated benefit-risk framework now requires reviewers to document residual safety uncertainties more explicitly. Even when efficacy endpoints are met in trials, uncertainty about long-term or off-target safety can prevent approval.
This heightened scrutiny means valuation models must account for an increased likelihood of CRLs and reconsider assumptions about trial design requirements. CEOs are advised to engage earlier with regulators and maintain transparency with investors regarding regulatory risks.
Demonstrating a drug’s incremental value over existing treatments has become essential before approval rather than after market entry. Companies that adapt their strategies to address this new regulatory reality may be better positioned for success.
"Regulatory uncertainty is no longer background noise. It is a material investment risk that reshapes how capital is deployed and pipelines are prioritized, and which companies ultimately succeed. Those that integrate regulatory realism into development strategy and investor communication will be better positioned than those that continue to play by the old rules."
